Trials / Completed
CompletedNCT01177826
Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix™) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 643 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 14 Weeks – 5 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess vaccine effectiveness of Rotarix in preventing rotavirus severe gastroenteritis among hospitalized infants, in Belgium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Sample collection | Stool sample |
Timeline
- Start date
- 2008-02-23
- Primary completion
- 2010-06-11
- Completion
- 2010-06-11
- First posted
- 2010-08-09
- Last updated
- 2020-01-03
Locations
29 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01177826. Inclusion in this directory is not an endorsement.